Tumor-shed PGE2 impairs IL2Rγc-signaling to inhibit CD4+ T cell survival: Regulation by theaflavins

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Chattopadhyay, Sreya ^a   Bhattacharyya, Sankar ^a   Saha, Baisakhi ^a   Chakraborthy, Juni ^a   Mohanty, Suchismita ^a   Sakib Hossain, Dewan Md ^a   Banerjee, Shuvomoy ^a   Das, Kaushik ^a   Sa, Gaurisankar ^a   Das, Tanya ^a  

^a BOSE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 2 RECEPTOR GAMMA C SUBUNIT; JANUS KINASE 3; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; STAT5 PROTEIN; THEAFLAVIN; UNCLASSIFIED DRUG; BIFLAVONOID; CATECHIN; IL2RG PROTEIN, HUMAN; STAT5A PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE CULTURE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADULT; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IMMUNE SYSTEM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM;

ADULT; APOPTOSIS; BIFLAVONOIDS; CATECHIN; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; DINOPROSTONE; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JURKAT CELLS; LYMPHOCYTE ACTIVATION; NEOPLASMS; STAT5 TRANSCRIPTION FACTOR; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 70350228294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007382     Document Type: Article

References (70)

1. Phipps RP, Stein SH, Roper RL (1991) A new view of prostaglandin E regulation of the immune response. Immunol Today 12: 349-352.
2. Goetzl EJ, An S, Smith WL (1995) Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J 9: 1051-1058.
3. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002) Prostaglandins as modulators of immunity. Trends Immunol 23: 144-150.
4. Passwell J, Levanon M, Davidsohn J, Ramot B (1983) Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity. Clin Exp Immunol 51: 61-68.
5. Cayeux SJ, Beverley PC, Schulz R, Dorken B (1993) Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant 12: 603-608.
6. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, et al. (2003) Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111: 727-735.
7. + T cells and their role in antitumor immune responses. J Exp Med 189: 753-756.
8. + T cell responses in antitumor immunity. Curr Opin Immunol 10: 588-594.
9. + tumor-infiltrating lymphocytes in human solid tumors. Immunol Res 14: 119-131.
10. + T cells in anti-tumor immune responses. Immunol Rev 222: 129-144.
11. + Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 120: 148-159.
12. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
13. Marzo AL, Lake RA, Robinson BW, Scott B (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59: 1071-1079.
14. Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, et al. (2008) Tumors Induce T Cell Apoptosis Through Receptor-Dependent and Receptor-Independent Pathways. J Immunol 180: 4687-4696.
15. Das T, Sa G, Hilston C, Kudo D, Rayman P, et al. (2008) GM1 and TNFa, overexpressed in renal cell carcinoma, synergize to induce T cell apoptosis. Cancer Research 68: 2014-2023.
16. Sa G, Das T, Moon C, Hilston CM, Rayman PA, et al. (2009) GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells. Cancer Res 69: 3095-3104.
17. Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, et al. (2007) Tumor-induced oxidative stress perturbs NFκB activity augmenting TNFα-mediated T cell death: Protection by curcumin. Cancer Research 67: 362-370.
18. Mandal D, Bhattacharyya S, Lahiry L, Chattopadhyay S, Sa G, et al. (2007) Black tea-induced decrease in IL-10 and TGF-β of tumor cells promotes Th1/Tc1 response in tumor-bearer. Nutrition Cancer 58: 213-221.
19. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A (1999) Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 20: 158-160.
20. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, et al. (2007) Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282: 15954-15964.
21. Mandal D, Bhattacharyya A, Lahiry L, Bhattacharyya S, Sa G, et al. (2005) Tumor-induced thymic involution via Inhibition of IL-7Rα and its JAK-STAT signaling pathway: Protection by Black Tea. Int. Immunopharmacol 6: 433-444.
22. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 66: 1114-1122.
23. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, et al. (2004) Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11: 328-339.
24. Minakuchi R, Wacholtz MC, Davis LS, Lipsky PE (1990) Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol 145: 2616-2625.
25. Spierings DC, Lemmens EE, Grewal K, Schoenberger SP, Green DR (2006) Duration of CTL activation regulates IL2 production required for autonomous clonal expansion. Eur J Immunol 36: 1707-1717.
26. Kolenko V, Rayman P, Roy B, Cathcart MK, O'Shea J, et al. (1999) Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood 93: 2308-2318.
27. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, et al. (2007) Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282: 15954-15964.
28. Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Boumpas DT (1992) Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL2 and IL2R alpha gene expression at multiple levels. J Immunol 148: 2845-2852.
29. Alava MA, DeBell KE, Conti A, Hoffman T, Bonvini E (1992) Increased intracellular cyclic AMP inhibits inositol phospholipid hydrolysis induced by perturbation of the T cell receptor/CD3 complex but not by G-protein stimulation. Association with protein kinase A-mediated phosphorylation of phospholipase C-gamma 1. Biochem J 284: 189-199.
30. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88: 386-401.
31. Wen R, Wang D, McKay C, Bunting DK, Marini CJ, et al. (2001) Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol Cell Biol 21: 678-689.
32. Webb LM, Vigorito E, Wymann MP, Hirsch E, Turner M (2005) Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 175: 2783-2787.
33. Saiagh S, Rigal D, Monier JC (1994) Effects of PGE2 upon differentiation and programmed cell death of suspension cultured CD4-CD8- thymocytes. Int J Immunopharmacol 16: 775-786.
34. Mastino A, Piacentini M, Grelli S, Favalli C, Autuori F, et al. (1992) Induction of apoptosis in thymocytes by prostaglandin E2 in vivo. Dev Immunol 2: 263-271.
35. Hilkens CM, Vermeulen H, van Neerven RJ, Snijdewint FG, Wierenga EA, et al. (1995) Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol 25: 59-63.
36. Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, et al. (2008) Contribution of p53-mediated transcription-dependent pathway in mammary epithelial carcinoma cell apoptosis by theaflavins. Apoptosis 13: 771-781.
37. Prasad S, Kaur J, Roy P, Kalra N, Shukla Y (2007) Theaflavins induce G2/ M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. Life Sci 81: 1323-1331.
38. Yang CS, Liao J, Yang GY, Lu G (2005) Inhibition of lung tumorigenesis by tea. Exp Lung Res 31: 135-144.
39. Dreger H, Lorenz M, Kehrer A, Baumann G, Stangl K, et al. (2008) Characteristics of catechin- and theaflavin-mediated cardioprotection. Exp Biol Med 233: 427-433.
40. Vermeer MA, Mulder TP, Molhuizen HO (2008) Theaflavins from black tea, especially theaflavin-3-gallate, reduce the incorporation of cholesterol into mixed micelles. J Agric Food Chem 56: 12031-12036.
41. Łuczaj W, Skrzydlewska E (2005) Antioxidative properties of black tea. Prev Med 40: 910-918.
42. Alves NL, Arosa FA, van Lier RA (2007) Common gamma chain cytokines: dissidence in the details. Immunol Lett 108: 113-120.
43. Nakajima H, Shores EW, Noguchi M, Leonard WJ (1997) The common cytokine receptor γ-chain plays an essential role in regulating lymphoid homeostasis. J Exp Med 185: 189-195.
44. Taniguchi T, Minami Y (1993) The IL2/IL2 receptor system: A current overview. Cell 73: 5-8.
45. Oakes SA, Candotti F, Johnson JA, Chen Y-Q, Ryan JJ, et al. (1996) Signaling via IL2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 5: 605-615.
46. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, et al. (1994) Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370: 153-157.
47. Zhang Q, Nowak I. Vonderheid EC, Rook AH, Kadin ME, et al. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93: 9148-9153.
48. Li C, Wu Z, Liu M, Pazgier M, Lu W (2008) Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci 17: 1624-1629.
49. Hengartner MO (2001) The biochemistry of apoptosis. Nature 407: 770-776.
50. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, et al. (1997) In vivo antitumor effects of murine interferon-gamma-inducing factor/ interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43: 361-367.
51. Reichert TE, Rabinowich H, Johnson JT, Whiteside T (1998) Mechanisms responsible for signaling and functional defects. J Immunother 21: 295-306.
52. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, et al. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Investig 99: 1173-1178.
53. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, et al. (1998) Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Investig 101: 2579-2588.
54. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL (2000) Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6: 1351-1364.
55. Watanabe S, Kagamu H, Yoshizawa H, Fujita N, Tanaka H, et al. (2003) The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 171: 5828-5836.
56. Shreedhar V, Moodycliffe AM, Ullrich SE, Bucana C, Kripke ML, et al. (1999) Dendritic cells require T cells for functional maturation in vivo. Immunity 11: 625-636.
57. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
58. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, et al. (2004) Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5: 1143-1148.
59. + T- cell response. Nat Rev Immunol 4: 595-602.
60. + T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 171: 6339-6343.
61. + T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220.
62. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, et al. (2004) Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11: 328-339.
63. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, et al. (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159: 3057-3067.
64. Goodwin JS, Bankhurst AD, Messner RP (1977) Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med 146: 1719-1734.
65. Astoul E, Edmunds C, Cantrell DA, Ward SG (2001) PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol 22: 490-496.
66. Baird AM, Thomis DC, Berg LJ (1998) T cell development and activation in Jak3-deficient mice. J Leukocyte Biol 63: 669-677.
67. Thomis DC, Berg LJ (1997) Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med 185: 197-206.
68. Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Boumpas DT (1992) Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL2 and IL2R alpha gene expression at multiple levels. J Immunol 148: 2845-2852.
69. Bhattacharyya A, Lahiry L, Mandal D, Sa G, Das T (2005) Black tea induces tumor cell apoptosis by Bax translocation, loss in mitochondrial transmembrane potential, cytochrome c release and caspase activation. Int J Cancer 117: 308-315.
70. Choudhuri T, Pal S, Das T, Sa G (2005) Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280: 20059-20068.